$4.46
8.78% today
Nasdaq, Feb 05, 04:21 pm CET
ISIN
CA10778Y3023
Symbol
BCTX
Sector
Industry

BriaCell Therapeutics Corp Stock price

$4.10
-2.77 40.29% 1M
-5.40 56.82% 6M
-4.38 51.62% YTD
-54.85 93.05% 1Y
-2.54 38.25% 3Y
-15.85 79.45% 5Y
-41.65 91.04% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.94 18.65%
ISIN
CA10778Y3023
Symbol
BCTX
Sector
Industry

Key metrics

Market capitalization $12.08m
Enterprise Value $5.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.45
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-29.98m
Free Cash Flow (TTM) Free Cash Flow $-23.75m
Cash position $5.79m
EPS (TTM) EPS $-13.27
Short interest 2.13%
Show more

Is BriaCell Therapeutics Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

BriaCell Therapeutics Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BriaCell Therapeutics Corp:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast BriaCell Therapeutics Corp:

Buy
100%

Financial data from BriaCell Therapeutics Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Oct '24
+/-
%
- -
-
100%
- Direct Costs 0.11 0.11
450% 450%
-
-0.11 -0.11
450% 450%
-
- Selling and Administrative Expenses 5.78 5.78
22% 22%
-
- Research and Development Expense 24 24
27% 27%
-
-30 -30
13% 13%
-
- Depreciation and Amortization 0.11 0.11
450% 450%
-
EBIT (Operating Income) EBIT -30 -30
14% 14%
-
Net Profit -17 -17
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about BriaCell Therapeutics Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BriaCell Therapeutics Corp Stock News

Neutral
GlobeNewsWire
one day ago
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 762,500 common shares at a public offering price of $4.00 p...
Neutral
GlobeNewsWire
2 days ago
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common shares in a best-efforts public offering. The offering is subject to...
Neutral
GlobeNewsWire
2 days ago
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce an unprecedented clinical response including resolution of a lung metastasis (breast cancer tumor tha...
More BriaCell Therapeutics Corp News

Company Profile

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Head office Canada
CEO William Williams
Employees 18
Founded 2006
Website www.briacell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today